Finance

Lists
Outlook: 62.5% bullish·0.0% bearish
Go to analysis
MIRM:NASDAQ
Mirum Pharmaceuticals Inc
$87.96
-1.94%
(-1.74) 1D
$87.69
-0.31% (-0.27)
Pre-market
Closed: Sep 28, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MIRM...
Open
$90.00
High
$91.25
Low
$84.71
Mkt. cap
5.71B
Avg. vol.
614.22K
Volume
1.33K
52-wk high
$130.00
52-wk low
$63.23
EPS
-$14.55
Beta
0.49
Shares outstanding
64.93M
No. of employees
433
Open
$90.00
High
$91.25
Low
$84.71
Mkt. cap
5.71B
Avg. vol.
614.22K
Volume
1.33K
52-wk high
$130.00
52-wk low
$63.23
EPS
-$14.55
Beta
0.49
Shares outstanding
64.93M
No. of employees
433
News stories
From web sources and news partners
About Mirum Pharmaceuticals Inc
CEO-
Employees433
Founded2018
HeadquartersFoster City, California, United States
SectorBiotechnology
Websitemirumpharma.com
Analyst ratings
Based on 11 analysts giving stock ratings to MIRM in the past 3 months
Strong buy
Buy
11
Hold
0
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for MIRM in the last 3 months.
Highest
Current $87.96
$195.00 (+121.69%)
Average
$143.82 (+63.51%)
Lowest
$118.00 (+34.15%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brian Skorney
Robert W. Baird
Buy
Maintained
$130.00
+47.8%
09/29/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$160.00
+81.9%
09/29/2026
Joseph Thome
TD Cowen
Buy
Maintained
$140.00
+59.2%
09/28/2026
Joseph Schwartz
Leerink Partners
Buy
Reiterated
$154.00
+75.1%
09/28/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
$137.00
+55.8%
09/28/2026
Swayampakula Ramakanth
H.C. Wainwright
Buy
Maintained
$195.00
+121.7%
09/28/2026
Jessica Fye
J.P. Morgan
Buy
Maintained
$118.00
+34.2%
08/11/2026
James Condulis
Stifel Nicolaus
Buy
Maintained
$136.00
+54.6%
08/06/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Reiterated
$140.00
+59.2%
08/05/2026
Lisa Walter
RBC Capital
Buy
Maintained
$135.00
+53.5%
08/06/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$137.00
+55.8%
08/06/2026
Unknown Analyst
J.P. Morgan
Buy
Initiated
$115.00
+30.7%
05/20/2026
Kalpit Patel
Wolfe Research
Buy
Initiated
$145.00
+64.8%
05/19/2026
Mani Foroohar
Leerink Partners
Buy
Maintained
$154.00
+75.1%
05/15/2026
Ryan Deschner
Raymond James
Buy
Maintained
$165.00
+87.6%
05/07/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Maintained
$138.00
+56.9%
05/07/2026
Joe Johoon Kim
RBC Capital
Buy
Maintained
$128.00
+45.5%
04/07/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
133.01M
148.93M
159.88M
176.24M
Cost of goods sold
25.54M
28.26M
28.80M
30.35M
Cost of revenue
25.54M
28.26M
28.80M
30.35M
Research and development expenses
42.96M
51.11M
97.91M
90.53M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
61.91M
74.13M
96.33M
81.47M
Operating expense
104.87M
125.24M
194.24M
172.00M
Total operating expenses
130.41M
153.50M
223.04M
202.34M
Operating income
2.60M
-4.57M
-63.16M
-26.10M
Other non operating income
-5.00K
-18.00K
102.00K
-11.14M
EBT including unusual items
2.64M
-4.96M
-789.68M
-65.54M
EBT excluding unusual items
2.64M
-4.96M
-64.38M
-36.21M
Income tax expense
-262.00K
767.00K
475.00K
1.69M
Effective tax rate
-9.91%
-15.45%
-0.06%
-2.58%
Other operating expenses
-
-
-
-
Net income
2.90M
-5.73M
-790.16M
-67.23M
Net profit margin
2.18%
-3.85%
-494.21%
-38.14%
Earnings per share
0.05
-0.12
-1.08
-0.80
Interest and investment income
3.25M
3.42M
3.40M
3.85M
Interest expense
-3.61M
-3.60M
-3.62M
-2.62M
Net interest expenses
-355.00K
-178.00K
-215.00K
1.23M
Depreciation and amortization charges
-
-
-
-
EBITDA
8.66M
1.51M
-56.29M
-19.17M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps